List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1025889/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
2	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
3	New insights to the MLL recombinome of acute leukemias. Leukemia, 2009, 23, 1490-1499.	7.2	363
4	Gain-of-function mutations in <i>interleukin-7 receptor-α</i> ( <i>IL7R</i> ) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 901-908.	8.5	307
5	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 2010, 115, 1006-1017.	1.4	305
6	<i>IKZF1</i> <sup>plus</sup> Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 1240-1249.	1.6	194
7	Genomics and drug profiling of fatal TCF3-HLFâ^'positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nature Genetics, 2015, 47, 1020-1029.	21.4	190
8	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
9	CircRNAs in hematopoiesis and hematological malignancies. Blood Cancer Journal, 2016, 6, e483-e483.	6.2	139
10	IKZF1 status as a prognostic feature in BCR-ABL1–positive childhood ALL. Blood, 2014, 123, 1691-1698.	1.4	129
11	Differentiation of muscle fiber types in the teleost Brachydanio rerio. Anatomy and Embryology, 1978, 153, 137-155.	1.5	125
12	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, 98, 1702-1710.	3.5	121
13	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	21.4	117
14	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia, 2012, 26, 902-909.	7.2	106
15	Hypoxia and HIF11± Repress the Differentiative Effects of BMPs in High-Grade Glioma. Stem Cells, 2009, 27, 7-17.	3.2	100
16	The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia, 2011, 25, 1840-1848.	7.2	96
17	Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia, 2012, 26, 2245-2253.	7.2	96
18	Wnt activation promotes neuronal differentiation of Glioblastoma. Cell Death and Disease, 2013, 4, e500-e500.	6.3	89

#	Article	IF	CITATIONS
19	Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia. Blood, 2011, 117, 4746-4758.	1.4	84
20	Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways. Cancer Cell, 2011, 19, 206-217.	16.8	80
21	Gene Expression–Based Classification As an Independent Predictor of Clinical Outcome in Juvenile Myelomonocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1919-1927.	1.6	74
22	Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia. Scientific Reports, 2019, 9, 14670.	3.3	69
23	Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood, 2017, 130, 643-654.	1.4	68
24	What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica, 2013, 98, 1226-1231.	3.5	65
25	<i>ETV6/RUNX1</i> â€like acute lymphoblastic leukemia: A novel Bâ€cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype. Genes Chromosomes and Cancer, 2017, 56, 608-616.	2.8	63
26	Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4030-E4039.	7.1	62
27	New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood, 2013, 121, 5064-5067.	1.4	53
28	Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. European Journal of Haematology, 2009, 83, 406-419.	2.2	51
29	Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. Leukemia, 2003, 17, 1557-1565.	7.2	49
30	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood, 2014, 124, 3577-3582.	1.4	49
31	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
32	Molecular Mechanisms of HIF-11 $\pm$ Modulation Induced by Oxygen Tension and BMP2 in Glioblastoma Derived Cells. PLoS ONE, 2009, 4, e6206.	2.5	45
33	Notch3/Jagged1 Circuitry Reinforces Notch Signaling and Sustains T-ALL. Neoplasia, 2014, 16, 1007-1017.	5.3	45
34	Post-transcriptional Silencing and Functional Characterization of the Drosophila melanogaster Homolog of Human Surf1. Genetics, 2006, 172, 229-241.	2.9	42
35	Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. PLoS ONE, 2010, 5, e13552.	2.5	42
36	Drosophila CAKI/CMG Protein, a Homolog of Human CASK, Is Essential for Regulation of Neurotransmitter Vesicle Release. Journal of Neurophysiology, 2005, 94, 1074-1083.	1.8	41

#	Article	IF	CITATIONS
37	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia. Journal of Leukocyte Biology, 2016, 99, 1077-1087.	3.3	41
38	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leukemia Research, 2016, 41, 36-42.	0.8	41
39	CirComPara: A Multiâ€Method Comparative Bioinformatics Pipeline to Detect and Study circRNAs from RNAâ€seq Data. Non-coding RNA, 2017, 3, 8.	2.6	41
40	AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia, 2013, 27, 1019-1027.	7.2	40
41	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. British Journal of Haematology, 2012, 158, 772-777.	2.5	39
42	Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes. Blood Advances, 2020, 4, 5902-5914.	5.2	39
43	Ultrafast molecular motor driven nanoseparation and biosensing. Biosensors and Bioelectronics, 2013, 48, 145-152.	10.1	37
44	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 170-181.	3.5	37
45	MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Medical Genomics, 2009, 2, 36.	1.5	35
46	Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer Journal, 2013, 3, e160-e160.	6.2	35
47	Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma. PLoS ONE, 2014, 9, e92707.	2.5	33
48	MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia, 2011, 25, 560-563.	7.2	31
49	AKR1C enzymes sustain therapy resistance in paediatric T-ALL. British Journal of Cancer, 2018, 118, 985-994.	6.4	31
50	The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp> â€ <scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711.	2.5	30
51	Development of immunohistochemical characteristics of intrafusal fibres in normal and de-efferented rat muscle spindles. Histochemistry, 1982, 74, 355-366.	1.9	29
52	Sample solution constraints on motor-driven diagnostic nanodevices. Lab on A Chip, 2013, 13, 866.	6.0	29
53	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232.	3.5	29
54	Expression Profiling of Circulating Microvesicles Reveals Intercellular Transmission of Oncogenic Pathways. Molecular Cancer Research, 2017, 15, 683-695.	3.4	29

#	Article	IF	CITATIONS
55	Label-Free Detection of Microvesicles and Proteins by the Bundling of Gliding Microtubules. Nano Letters, 2018, 18, 117-123.	9.1	29
56	Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis. Leukemia, 2019, 33, 333-347.	7.2	28
57	Immunohistochemical differences in myosin composition among intrafusal muscle fibres. Histochemistry, 1981, 73, 65-74.	1.9	27
58	Skeletal muscle fibre type specification during embryonic development. Journal of Muscle Research and Cell Motility, 2002, 23, 65-69.	2.0	27
59	TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia, 2021, 35, 389-403.	7.2	26
60	A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica, 2005, 90, 890-8.	3.5	26
61	Proâ€inflammatory cytokines favor the emergence of ETV6â€RUNX1â€positive preâ€leukemic cells in a model of mesenchymal niche. British Journal of Haematology, 2020, 190, 262-273.	2.5	25
62	Array-Based Comparative Genomic Hybridization Analysis Reveals Chromosomal Copy Number Aberrations Associated with Clinical Outcome in Canine Diffuse Large B-Cell Lymphoma. PLoS ONE, 2014, 9, e111817.	2.5	25
63	PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. Leukemia, 2013, 27, 992-995.	7.2	24
64	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272.	1.8	24
65	Clinical significance of recurrent copy number aberrations in Bâ€lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts. British Journal of Haematology, 2017, 178, 583-587.	2.5	23
66	Antibodies Covalently Immobilized on Actin Filaments for Fast Myosin Driven Analyte Transport. PLoS ONE, 2012, 7, e46298.	2.5	22
67	ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica, 2019, 104, 533-545.	3.5	21
68	Mutations of <i>SETBP1</i> and <i>JAK3</i> in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget, 2016, 7, 28914-28919.	1.8	21
69	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget, 2016, 7, 13886-13901.	1.8	20
70	Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis. Scientific Reports, 2016, 6, 34449.	3.3	20
71	Low <i>PKCα</i> expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget, 2014, 5, 5234-5245.	1.8	20
72	CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Frontiers in Genetics, 2019, 10, 88.	2.3	19

#	Article	IF	CITATIONS
73	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. Oncotarget, 2017, 8, 42398-42413.	1.8	19
74	The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica, 2006, 91, 765-71.	3.5	19
75	Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 2015, 29, 2107-2110.	7.2	18
76	Antileukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL. Molecular Cancer Therapeutics, 2018, 17, 1705-1716.	4.1	18
77	Zebrafish CTH1, a C3H zinc finger protein, is expressed in ovarian oocytes and embryos. Development Genes and Evolution, 1999, 209, 443-446.	0.9	17
78	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. Journal of Biological Chemistry, 2007, 282, 29384-29393.	3.4	17
79	PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia, 2010, 24, 232-235.	7.2	17
80	Mesenchymal stem cells from Shwachman–Diamond syndrome patients display normal functions and do not contribute to hematological defects. Blood Cancer Journal, 2012, 2, e94-e94.	6.2	17
81	<i>LCK</i> over-expression drives STAT5 oncogenic signaling in <i>PAX5</i> translocated BCP-ALL patients. Oncotarget, 2015, 6, 1569-1581.	1.8	17
82	Myosin isoforms in hindlimb muscles of normal and dystrophic (ReJ129 dy/sol;dy) mice. Muscle and Nerve, 1992, 15, 199-208.	2.2	16
83	Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leukemia Research, 2013, 37, 928-935.	0.8	16
84	Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica, 2013, 98, e164-e165.	3.5	16
85	Sensing protein antigen and microvesicle analytes using high-capacity biopolymer nano-carriers. Analyst, The, 2016, 141, 836-846.	3.5	16
86	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	2.5	16
87	MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood, 2021, 138, 1953-1965.	1.4	16
88	An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death and Disease, 2016, 7, e2047-e2047.	6.3	15
89	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncology Reports, 2007, 18, 417-23.	2.6	15
90	Expression of carp-cdx1, a caudal homolog, in embryos of the carp, Cyprinus carpio. Roux's Archives of Developmental Biology, 1995, 204, 369-377.	1.2	13

#	Article	IF	CITATIONS
91	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia. Human Molecular Genetics, 2014, 23, 590-601.	2.9	13
92	New data on robustness of gene expression signatures in leukemia: comparison of three distinct total RNA preparation procedures. BMC Genomics, 2007, 8, 188.	2.8	12
93	<scp>DNA</scp> methylation and targeted sequencing of methyltransferases family genes in canine acute myeloid leukaemia, modelling human myeloid leukaemia. Veterinary and Comparative Oncology, 2017, 15, 910-918.	1.8	12
94	CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. Frontiers in Cell and Developmental Biology, 2020, 8, 613540.	3.7	12
95	DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study. Haematologica, 2011, 96, 1886-1887.	3.5	11
96	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. Oncotarget, 2015, 6, 1382-1395.	1.8	11
97	Differential susceptibility of early steps in carp (Cyrinus carpio) development to ?-amanitin. Roux's Archives of Developmental Biology, 1992, 202, 61-65.	1.2	10
98	The segregation of inner and outer cells in porcine embryos follows a different pattern compared to the segregation in mouse embryos. Roux's Archives of Developmental Biology, 1993, 203, 113-116.	1.2	10
99	The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group. Blood, 2008, 112, 753-753.	1.4	10
100	Philadelphia-Like Signature In Childhood Acute Lymphoblastic Leukemia: The AIEOP Experience. Blood, 2013, 122, 353-353.	1.4	9
101	Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1409-1409.	1.4	9
102	Different outcomes of allogeneic hematopoietic stem cell transplant in a pair of twins affected by juvenile myelomonocytic leukemia. International Journal of Hematology, 2014, 99, 208-212.	1.6	7
103	Acute Leukemia Subclassification: A Marker Protein Expression Perspective. Hematology, 2004, 9, 165-170.	1.5	6
104	Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. Journal of Experimental Medicine, 2011, 208, 1333-1333.	8.5	6
105	Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Leukemia, 2012, 26, 1717-1719.	7.2	6
106	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
107	New Data on Robustness of Gene Expression Signatures in Leukemia: Comparison of Three Distinct Total RNA Preparation Procedures Blood, 2006, 108, 4288-4288.	1.4	6
108	Evolution of Sub-Clones with KRAS Mutations In Pediatric Patients with MLL-AF4 Rearrangements. Blood, 2011, 118, 2454-2454.	1.4	6

#	Article	IF	CITATIONS
109	Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia. Leukemia, 2006, 20, 888-891.	7.2	5
110	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
111	TELEOST YOLK CELL FUNCTION ON BLASTODERM DIFFERENTIATION AND MORPHOGENESIS. Animal Biology, 2000, 50, 37-51.	0.4	4
112	The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment. Blood, 2014, 124, 131-131.	1.4	4
113	Migration of Acute Lymphoblastic Leukemia Cells into the Central Nervous System Is Regulated By VEGF. Blood, 2015, 126, 2634-2634.	1.4	4
114	Embryonic development in the pig up to the 64-cell stage, with reference to DNA replication and cell cycle times from the third cleavage division. Theriogenology, 1993, 39, 919-928.	2.1	3
115	Isolation of carp cDNA clones, representing developmentally-regulated genes, using a subtractive-hybridization strategy. Roux's Archives of Developmental Biology, 1996, 205, 460-467.	1.2	3
116	The carp homeobox gene Ovx1 shows early expression during gastrulation and subsequently in the vagal lobe, the facial lobe and the ventral telencephalon. Development Genes and Evolution, 1998, 208, 56-59.	0.9	3
117	Muscle Plasticity and High Throughput Gene Expression Studies. Journal of Muscle Research and Cell Motility, 2004, 25, 231-234.	2.0	3
118	Nextâ€generation sequencing of PTEN mutations for monitoring minimal residual disease in Tâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28025.	1,5	3
119	DNA probes to repetitive sequences for the analysis of porcine genomic DNA with reference to DNA methylation. Theriogenology, 1993, 39, 1313-1320.	2.1	2
120	Non-medical applications of non-invasive prenatal diagnosis: Ethical issues. Forensic Science International: Genetics Supplement Series, 2011, 3, e554-e555.	0.3	2
121	Blastoderm Structure, Cell Migration and Formation of the Embryonic Shield During Gastrulation in the Carp (Cyprinus carpio); a Scanning Electron Microscopic Study. European Journal of Morphology, 1998, 36, 65-75.	0.8	2
122	DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation – A REPORT FROM the lbfm-STUDY GROUP Blood, 2009, 114, 11-11.	1.4	2
123	Copy Number Variations and IKZF1 Mutations In Pediatric CML. Blood, 2013, 122, 1473-1473.	1.4	2
124	Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia. Oncology Reports, 2006, 15, 341-6.	2.6	2
125	Gastrulation in Cyprinids: Morphogenesis and Gene Expression. Animal Biology, 1995, 46, 115-133.	0.4	1
126	Teleost Yolk Cell Function On Blastoderm Differentiation and Morphogenesis. Animal Biology, 2000, 50, 37-51.	0.4	1

#	Article	IF	CITATIONS
127	Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties. Blood, 2018, 132, 1296-1296.	1.4	1
128	Reverse Phase Protein Assay (RPPA) Defines Specific Patterns in Childhood Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2510-2510.	1.4	1
129	Poor Prognosis for IKZF1 Intra-Gene Deletions in Pediatric Phâ^' B-Cell Precursor Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3518-3518.	1.4	1
130	Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia. Blood, 2015, 126, 2534-2534.	1.4	1
131	Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. Blood, 2015, 126, 903-903.	1.4	1
132	Specific Circulating Microvesicles (cMVs) Populations in Paediatric ALL. Blood, 2011, 118, 933-933.	1.4	1
133	Subunit a of Coagulation Factor XIII As a New Biomarker in Childhood Acute Lymphoblastic Leukemia?. Blood, 2014, 124, 5346-5346.	1.4	1
134	Mesoderm differentiation in explants of carp embryos. Roux's Archives of Developmental Biology, 1994, 204, 20-29.	1.2	1
135	Aberrantly expressed TET1 in T-ALL regulates DNA repair and leukemic growth via maintenance of 5-hydroxymethylome and can be antagonized by the parp inhibitor Olaparib. Experimental Hematology, 2017, 53, S129-S130.	0.4	Ο
136	Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse. Blood, 2008, 112, 755-755.	1.4	0
137	STAT5 Phosphorylation Status by Flow Cytometry Is a Rapid and Reliable Tool for Diagnosis and Follow-up of Juvenile Myelomonocytic Leukemia. Blood, 2010, 116, 2751-2751.	1.4	0
138	High Risk Acute Lymphoblastic Leukemia with Rapid NOD/SCID Engraftment Is Characterized by High Protein Expression of CYCLIN B, Beta-CATENIN, ANNEXIN I and Decreased PKC Alpha Activation. Blood, 2011, 118, 1457-1457.	1.4	0
139	Microvesicles Transcripts As Hallmark and Vector From Leukemic Parental Cells. Blood, 2012, 120, 1459-1459.	1.4	Ο
140	Mosaic Distribution of RAS Pathway Mutated and Non Mutated Cells in Bone Marrow of Juvenile Myelomonocytic Leukemia Blood, 2012, 120, 2818-2818.	1.4	0
141	CI-FISH, GEP, and SNPs Correlate Genomic Categories with Risk Stratification in Children with T-ALL Blood, 2012, 120, 2485-2485.	1.4	Ο
142	MLLT10 Gene Promiscuity Unravels Involvement of RNA Processing Genes in Pediatric T-Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1431-1431.	1.4	0
143	PAX5 Fusion Genes Activate The STAT5 Signaling Pathway Through Lck Over-Expression. Blood, 2013, 122, 3738-3738.	1.4	0
144	Abstract 433: Triplication of HMGN1 promotes B cell acute lymphoblastic leukemia (B-ALL) through		0

suppression of H3K27me3. , 2014, , .

GEERTRUIJ TE KRONNIE

#	Article	IF	CITATIONS
145	Refinement of IKZF1 Genomic Status in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3785-3785.	1.4	0
146	Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy. Blood, 2014, 124, 970-970.	1.4	0
147	Secondary Mutations of JAK3 and SETBP1 in Juvenile Myelomonocytic Leukemia and Their Propagating Capacity; A Report from the AlEOP Study Group. Blood, 2014, 124, 4625-4625.	1.4	0
148	TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib. Blood, 2016, 128, 737-737.	1.4	0
149	Bone Marrow Mesenchymal Stromal Cells and Inflammation Contribute to ETV6-RUNX1+ Preleukemic Cells Persistence and DNA Damaging. Blood, 2018, 132, 3918-3918.	1.4	0
150	Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2019, 134, 745-745.	1.4	0
151	Abstract 2541: MicroRNA-497~195 cluster suppresses acute lymphoblastic leukemia growth by targeting CCND3/CDK4 and inhibiting cell cycle progression. , 2020, , .		0
152	Incidence and Therapeutic Implications of Germline <i>TP53</i> Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort. Blood, 2020, 136, 43-44.	1.4	0